Factors Influencing the Efficacy of Low-Dose Spironolactone in Adults with Chronic Kidney Disease and Type 2 Diabetes: A post hoc Analysis.

ABSTRACT:

Introduction

We previously reported the efficacy and safety of low-dose (12.5 mg/day) spironolactone for chronic kidney disease (CKD) with diabetes. Few studies have examined the characteristics of patients who may have reduced urinary albumin-creatinine ratio (UACR) on mineralocorticoid receptor antagonists. In this study, we aimed to identify the clinical characteristics of patients prone to benefit from UACR reduction with low-dose spironolactone.

Methods

This was a post hoc analysis of a previous trial and included 55 patients assigned to the spironolactone group. Univariate regression analysis was performed to determine the association between the change in UACR after 24 weeks of low-dose spironolactone administration and baseline exploratory parameters. Multiple regres

SUBMITTER: Takayama S 

PROVIDER: S-EPMC12845521 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature